Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review
Atul N Khadse1, Mayank K Sharma1, Prashant R Murumkar1
1Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara, India.
Abstract:
Development of new anticoagulants has been in constant demand throughout the world due to increasing rate of morbidity and mortality caused by thrombotic diseases. Factor Xa (FXa), one of the enzymes and validated target for anticoagulation, regulates the production of thrombin in the coagulation cascade. The importance of oral FXa inhibitors like rivaroxaban, apixaban and edoxaban in thromboembolic conditions is well supported by increasing number of patents and research publications during the recent years. Direct FXa inhibitors as antithrombotic agents offer selective, efficacious and orally active therapy with respect to the other traditional anticoagulants. Newly developed patented molecules are mainly structural bioisosteres of existing drugs and have exhibited better efficacy and safety profile. Development of antidotes for oral direct FXa inhibitors is in pipeline and their expected approval for therapeutic purposes will be further beneficial to anticoagulation therapy. This review is mainly focused on industrial and academic patents on the discovery of direct FXa inhibitors. The review covers patented compounds from December 2011 till date, describing various structural modifications along with biological activity data and advances in the process and formulation technologies of the reported FXa inhibitors.
Insights
New anticoagulants, particularly direct Factor Xa (FXa) inhibitors, are crucial for treating thrombotic diseases. This review details patented FXa inhibitors, focusing on structural modifications and therapeutic advancements.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Drug Discovery
Background:
- Thrombotic diseases cause significant morbidity and mortality globally.
- Factor Xa (FXa) is a validated target for anticoagulation therapy.
- Oral direct FXa inhibitors offer selective and effective treatment for thromboembolic conditions.
Purpose of the Study:
- To review industrial and academic patents on direct FXa inhibitors.
- To cover patented compounds from December 2011 to the present.
- To describe structural modifications, biological activity, and technological advances.
Main Methods:
- Patent literature analysis.
- Review of scientific publications.
- Analysis of structural modifications and biological data.
Main Results:
- Numerous patented direct FXa inhibitors have been developed.
- New molecules often feature structural bioisosterism for improved efficacy and safety.
- Advances in process and formulation technologies are reported.
Conclusions:
- Direct FXa inhibitors represent a significant advancement in anticoagulation.
- Ongoing research and patenting activity highlight the field's dynamism.
- Development of antidotes for oral FXa inhibitors is anticipated to further enhance therapy.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Transcription Factors
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Extraction: Advanced Methods


